The Latest

Fewer than half of Americans feel that the healthcare system is good enough. (Over 20% rate it as poor.) A large percentage of doctors question the healthcare system's effectiveness in meeting patients’ needs. Almost half of physicians report burnout -- emotional exhaustion, depersonalization, reduced sense of personal accomplishment. And as indicated, these trends are only worsening. RegenMed’s business model is firmly rooted in the primacy of healthcare professionals. It is they who – by virtue of education, experience and disposition -- are able to diagnose, treat, and engage with patients in a meaningful way. It is they who can identify the most important clinical issues, the most sensible and cost-effective approach to addressing those issues, and the areas where new products and treatment protocols will have the broadest impact. RegenMed’s Circles – especially its Physician-Owned Circles – empower the clinical independence of any healthcare professional. They do not interrupt normal clinical flow, but make it more meaningful for both clinicians and patients. And, critically, they return to physicians a large amount of the financial value which they deserve. There are over 1 million active physicians in the U.S., and almost 2 million in the European Union. Very few of them do not want to exercise their best clinical judgment on behalf of their patients. Very few of them do not want the tools, data, and ethical financial incentive which will allow them to do so. RegenMed’s strong monthly growth only confirms this strong demand among physicians all over the world. We are confident that this is only the beginning of “zero to one” business model which can have a profound and beneficial impact on healthcare.

“Zero to One” is a concept coined by Peter Thiel (PayPal, Palantir, Founders Fund). It denotes a company which not only identifies a new and large market, but also develops the ability to capture a good deal of that market’s value. The image to the left is a large expanse of sand with a small pocket of oil bubbling to the surface. From those two simple ingredients the petrochemical and semiconductor industries evolved. However, it was not enough to recognize the value of sand and viscous crude oil. It was also necessary to build the infrastructure and processes necessary to capture that value.RegenMed was founded — and operates — on the premise that real world data is to healthcare what sand was to semiconductors or crude to refined petrochemicals. It is the commonplace — but uncaptured and unrefined raw materials -- from which the most valuable healthcare innovations will emerge.The high-quality datasets which can be generated from real world data are of immense value to healthcare insurers, providers, product manufacturers, and of course patients. Physicians — closely collaborating with each other — are the key to identifying the most promised real-world data, capturing it, and helping unlock its value. RegenMed’s clients prove this every day.Healthcare in the U.S. is broken. There are a few more important problems for us to solve. The key is enabling and incentivizing physicians to generate the evidence based on real-world treatments and correlated patient outcomes. RegenMed has built the patented platforms and processes which do that on a regular basis. We and our clients welcome your investment so that we can rapidly expand upon this early zero to one success. The opportunities are enormous.

Register for our live-streamed Investors webinar this Tuesday, November 12 at 6:30 pm EST, GMT-5. Michael Tierney, our Chief Executive Officer and Co-Founder, will be covering our addressable markets, product market fit, recurring revenue growth, intellectual property, and use of proceeds. There will be ample time for questions and answers. A recording of the webinar will also be available afterwards.

Americans pay more for healthcare than any other country, and yet are less healthy by many measures. Moreover, healthcare costs continue to rise faster than general inflation. How can this be? A major reason is the cost of clinical trials. Clinical trials are how we ensure that a drug, device or other medical product is safe and effective – obviously an important goal. However, the average clinical trial today can easily cost $60,000,000 and last over seven years. A typical number of patients in a trial is at least 500, who are asked to answer, for example, 300 or questions. That is $120,000 per patient, and $200,000 per question. This means that only the largest companies can afford clinical trials. That they will charge high prices for approved products. That their clinical trials will be narrowly focused on products which will give them the greatest profitability. That many medical products which could have a greater impact on more people, for less cost, will never see the light of day. Lower Costs Drive Higher Quality and More Accessibility The obvious solution is to reduce the cost required to establish the safety and efficacy of medical products. Lower cost does not mean lower quality. To the contrary, it often means better quality, more accessibility, and greater innovation. Henry Ford’s Model Ts were lower cost, better, faster and available to far more people than the cars of his competitors. Space X is committed to bringing down the cost per kilogram of a rocket launch from several thousands of dollars to $10. Why should medical products be more expensive and less accessible each year? A RegenMed Circle can generate a clinically and statistically significant dataset involving 500 patients and 300 questions for only $6,700. That is $13 per patient, and $22 per question. This is made possible by the technology and processes described in RegenMed’s patent, Method and System For Processing Large Amounts Of Real-World Evidence.In many cases, there will of course be additional costs beyond clinical trials in obtaining final regulatory approval for a particular product. But the ability to develop high-quality clinical datasets at a small fraction of current costs is a major step in bringing better, more useful and more accessible products to market. For more information on how RegenMed is supporting physicians and product manufacturers around the world deliver evidence-based care to more patients, at a lower cost, see our Latest page.This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Nick: ‍This is Nick Tierney with RegenMed Circles. And I'm here with Michael Strøm, a shockwave specialist and sexologist out of Denmark.Michael: Yeah. I'm happy to be here today. I'm coming from manual therapy and started working with shockwave back in 2016. So, my daily work consists of shockwave for erectile dysfunction, Peyronie's disease, chronic pelvic pain and incontinence. So that is where I am today, and today I'm one of the leading shockwave guys in the world and in this field, participating in many conferences, doing keynote speeches and doing a lot of education. So that's also why tracking up data is becoming more and more important to me.Nick: So, we’re relatively new to shockwave ourselves. But in the short time we become aware of it, we do recognize there's a lot of evidence for shockwave, and a growing body of evidence in the literature. So why is there a need for data if there's already a lot of publications? Michael:We have Storz, we have MTS, we have Richard Wolf, we have Inceler, we have StimWave™, we have Medispec, we have so many different devices utilizing the three ways of generating the shock wave. And when we look at them in all the studies - it's different protocols - we can see everyone is having an effect, with the different devices and in different areas. But if we want to, as we’re wanting, an expert group I’m a part of in Europe, with different urologists, cure pain leaders, which is men's health shockwave, if we want to try to do a common protocol of getting a better sense of what is the right way to do, then we need to track every specific device on how many pulses and we actually need to go down to what kind of applicator is. So, if I take the Storz device, the electromagnetic, there are two different applicators. If we take the Richard Wolf, Elvation®, there are five different applicators, and we take the MTS - and that's electrohydraulic - they have three different hand pieces. So, all the things we need to track and incorporate to see how we're getting the best effect. For me, when I have all the equipment inside, I'm going to randomize every time I'm getting a client in, I say "Okay, for this indication I will believe this device will be the best. So, then I need to do my notes, I need to put in how many pulses, what kind of energy, how many sessions and what hand pieces they use because then we can start getting some really valuable data for us as clinicians but also for the companies to see where they need to go with the development of the devices. Nick: Very interesting. So, you’ve launched some Circles which are focused on these four indications that you commonly treat. Talk us a little bit through those Circles. How did you design them? What are their main objectives and missions? Etc.Michael: For erectile dysfunction, we are tracking the erectile function - how much is the improvement with tracking a life quality, so here you can really get a good hold on your clients to track them over time and get them in again because our patient is already reoccurring, coming in back again and again, that is easier to getting a new client. For Peyronie's disease we are tracking different aspects with tracking pain, function, how much the symptom is bothering them, quality of life and erectile function. So, here we can distinguish from what is coming from the curvature, what is from the erection, and with these kinds of very sensitive, you can really ‘hold them in the hand’ for a long while because this is a long game, this is a 12 to 24 months progress you're gonna stop. With pelvic pain, which is quite interesting, we're looking at erectile function that is normally away when they have pelvic pain, we're looking at the intensity of the pain, where it's located, how is it going to progress and how the quality of life is going to turn out. So, this is also something that's reassuring the client that we have access to take care of it because we normally been met and then forgotten the traditional system. For incontinence we're looking into quality of life, we're looking into how much leakage there is, how many times a day and how I said the function of the pelvic floor. The issue is that I've been having these questions from clients for years: “How do you track your outcomes?”, “What do you do?” and I’ve always been saying: “Well, I'm just meaning it - what you see is what you get. So, I'm also the secretary, I’m also the IT guy, I’m the marketing guy, and I'm doing the treatment as well. So, I didn’t have the capacity with the high amount of clients. I had to call everyone or write them an email, setting up this complex system. So, in that way the system with RegenMed is really making that easy for me, that's cheating a bit.Nick: It sounds like you also work with colleagues quite a bit and help give them guidance, and instruction, and standards that are emerging within this exciting field. How does the Circle play a role in that? Is there an opportunity for other - either new or even experienced shockwave practitioners - to benefit from joining into your study or Circle, and participating? And if so, what are the benefits for that?Michael: The key point is really that you are going to join my Circle, I’ve already been doing the hard work, so you can just log in, then you're going to start tracking the data, you’re going to have all these easy things handed directly to you. The second thing is that you’re going to have a big care for your clients. Every time they submit a new data point, you can engage them so they can either come back in or you can say “okay, I can see it's going good”. So, we just let it go for two more months or three months. And you're going to have this reoccurrence of the clients. You are going to have a different bond with them. The third thing is that with all the data you get, you are going to be comparing yourself to me and all the other guys in the Circles. So, you know how you're doing, you can benchmark yourself and have a lot of access to knowledge. You can see how I'm progressing. And in that way, you're going to lead your clients to a better state. So please join the Circle. It will help all of us to create better protocols for the different areas. And we need to have better protocols so we can attend to the care of our clients in the best possible matter.‍